In recent years, with the increase in the number of patients, the increase in per capita disposable income, and the expansion of diabetes drug indications, China's diabetes drug market has shown a growing trend
year by year.
The data shows that in 2021, the sales scale of terminal oral diabetic drugs in China's urban public hospitals, county-level public hospitals, urban community centers and township health centers (referred to as China's public medical institutions) will exceed 20 billion yuan
.
In the face of the huge development prospects of the diabetes drug market, domestic enterprises are constantly increasing the research and development
of related drugs.
At the same time, multinational pharmaceutical companies are also accelerating the promotion of more new drugs in
China.
Recently, Eli Lilly announced that the listing application of tilopotide injection submitted in China has been accepted by CDE
.
Tirzepatide is a GIP/GLP-1 receptor dual agonist that belongs to the "first-in-class" drug
.
It is reported that in May this year, the drug was just approved by the US FDA for improving blood glucose control
in adults with type 2 diabetes.
The drug is administered subcutaneously once a week, the dose
can be adjusted according to tolerability.
The listing in China is expected to benefit Chinese diabetics
soon.
At present, thiirpo peptide also lays out the research and development
of obesity, cardiovascular system disease, NASH, sleep apnea, kidney disease (CKD) and other indications.
According to the China Drug Clinical Trial Registration and Information Publicity Platform, Eli Lilly has conducted five related clinical trials in China, in addition to the completed clinical trial of type 2 diabetes, there are three ongoing international multicenter Phase 3 clinical trials, the indications are obstructive sleep apnea and obesity, overweight/obesity, and reducing the compound outcomes
of major adverse cardiovascular events in patients with type 2 diabetes mellitus with an increased risk of cardiovascular disease.
It is worth mentioning that, according to incomplete statistics, China's State Drug Administration is processing 18 listing application acceptance numbers from Eli Lilly, involving 9 drugs, of which migraine drugs, insulin drugs and anti-tumor drugs are each 2
.
In addition to Lilly's thiolpopeptide injection, the recent application for the listing of the new Chinese medicine class 1.
1 new drug QiHuang Mingmu capsule submitted by Shijiazhuang Yiling Pharmaceutical has also been accepted by the CDE for the treatment of diabetic retinopathy
.
According to a press release from Ling Pharmaceutical, Qihuang Mingmu capsules can effectively reduce capillary permeability, reduce retinal and macular edema and bleeding, and also help stabilize patient blood glucose and curb the development of simple lesions into value-added lesions
.
In addition, Hengrui Pharmaceutical also issued an announcement in August that the company received the approval of the State Drug Administration to issue a "Drug Clinical Trial Approval Notice" on HR20014 injection, and will carry out clinical trials
of diabetes indications in the near future.
According to the data, HR20014 injection can achieve a smooth and sustained hypoglycemic effect, taking into account fasting blood glucose and postprandial blood glucose control
.
In fact, in recent years, the enthusiasm of domestic pharmaceutical companies in the field of diabetes drugs is very high
.
The industry expects that with the help of policies, the development of the domestic insulin industry will also accelerate
.
It is understood that the "Healthy China Action (2019-2030)" released in 2019 listed diabetes prevention and control actions as one of the 15 major actions
.
Under the background that diabetes management is getting more and more attention from the Chinese government, the industry believes that in the future, the superimposed medical insurance policy and drug collection, as well as the efforts of many pharmaceutical companies, the domestic diabetes drug market may usher in great changes
.
Disclaimer: In no event shall the information or opinions expressed herein constitute investment advice
to any person.
